It is also well proven that disrupting p53/MDM2 protein binding would restore wild-type p53 protein activity and subsequently enhance the apoptotic pathway in cancer and even normal cells [38], which may be valuable in treating different types of cancer cell pathway proliferation. The gene discussed is TP53; the disease is cancer.